Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor

Journal of Clinical Investigation

Volumn 115, Issue 7, 2005, Pages 1828-1838

  Weaver, Joel G R ^a,b,c   Tarze, Agathe ^d   Moffat, Tia C ^e   Lebras, Morgane ^d   Deniaud, Aurelien ^d   Brenner, Catherine ^d   Bren, Gary D ^b   Morin, Mario Y ^e   Phenix, Barbara N ^c   Dong, Li ^a,c   Jiang, Susan X ^f   Sim, Valerie L ^g   Zurakowski, Bogdan ^f   Lallier, Jessica ^e   Hardin, Heather ^b   Wettstein, Peter ^b   Van Heeswijk, Rolf P G ^c   Douen, Andre ^c   Kroemer, Romano T ^h   Hou, Sheng T ^f   Bennett, Steffany A L ^e   Lynch, David H ⁱ   Kroemer, Guido ^j   Badley, Andrew D ^b,k   more..

^a UNIVERSITY OF OTTAWA   (Canada)

^b MAYO CLINIC   (United States)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e Department of Biochemistry Microbiology and Immunology   (France)

^f NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h SANOFI   (France)

ⁱ Amnis Corporation   (United States)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k Mayo Clinic   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; NELFINAVIR; PROTEIN SUBUNIT; PROTEINASE INHIBITOR; RITONAVIR; STAPHYLOCOCCUS ENTEROTOXIN B;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL PROTECTION; CHANNEL GATING; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FATALITY; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE PERMEABILITY; MIDDLE CEREBRAL ARTERY OCCLUSION; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SEPTIC SHOCK; STROKE; TOXIC HEPATITIS;

ANIMALS; ANTIBODIES; APOPTOSIS; CEREBROVASCULAR ACCIDENT; DISEASE MODELS, ANIMAL; FEMALE; HEPATITIS; HIV PROTEASE INHIBITORS; HUMANS; JURKAT CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MITOCHONDRIAL ADP, ATP TRANSLOCASES; MODELS, MOLECULAR; NELFINAVIR; RITONAVIR; SHOCK, SEPTIC; SIGNAL TRANSDUCTION;

EID: 22144498421     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI22954     Document Type: Article

References (66)

1. Phenix, B.N., Cooper, C., Owen, C., and Badley, A.D. 2002. Modulation of apoptosis by HIV protease inhibitors. Apoptosis. 7:295-312.
2. Zhong, D.S., et al. 2002. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22:1560-1566.
3. Gaedicke, S., et al. 2002. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res. 62:6901-6908.
4. Pajonk, F., Himmelsbach, J., Riess, K., Sommer, A., and McBride, W.H. 2002. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res. 62:5230-5235.
5. Estaquier, J., et al. 2002. Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death. J. Virol. 76:5966-5973.
6. Sloand, E.M., Young, N.S., Sato, T., Kim, S., and Maciejewski, J.P. 1998. Inhibition of interleukin-1beta-converting enzyme in human hematopoietic progenitor cells results in blockade of cytokine-mediated apoptosis and expansion of their proliferative potential. Exp. Hematol. 26:1093-1099.
7. Weichold, F.F., et al. 1999. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J. Hum. Virol. 2:261-269.
8. Sloand, E.M., et al. 1999. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood. 94:1021-1027.
9. Sloand, E.M., et al. 2000. Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells. Blood. 96:2735-2739.
10. Ghibelli, L., et al. 2003. Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. Biochem. Pharmacol. 66:1505-1512.
11. Phenix, B.N., Lum, J.J., Nie, Z., Sanchez-Dardon, J., and Badley, A.D. 2001. Anti-apoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood. 98:1078-1085.
12. Matarrese, P., et al. 2003. Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. J. Immunol. 170:6006-6015.
13. Barreiro, P., Soriano, V., Casas, E., and Gonzalez-Lahoz, J. 2002. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS. 16:245-249.
14. Benito, J.M., et al. 2002. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors. AIDS Res. Hum. Retroviruses. 18:1379-1388.
15. Kravcik, S., et al. 2001. Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavit matched for viral exposure. HIV Clin. Trials. 2:160-170.
16. Landay, A.L., et al. 2003. Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. J. Infect. Dis. 188:1444-1454.
17. Zeldin, R.K., and Petruschke, R.A. 2004. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J. Antimicrob. Chemother. 53:4-9.
18. Zender, L., et al. 2003. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. U. S. A. 100:7797-7802.
19. Song, E., et al. 2003. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9:347-351.
20. Kovalovich, K., et al. 2001. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL J. Biol. Chem. 276:26605-26613.
21. Jiang, H., et al. 1995. Murine CD8+ T cells that specifically delete autologous CD4+ T cells expressing V beta 8 TCR: a role of the Qa-1 molecule. Immunity. 2:185-194.
22. Miethke, T., et al. 1992. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J. Exp. Med. 175:91-98.
23. Aoki, Y., et al. 1995. Protective effect of granulocyte colony-stimulating factor against T-cell-meditated lethal shock triggered by superantigens. Blood. 86:1420-1427.
24. Mullen, R.J., Buck, C.R., and Smith, A.M. 1992. NeuN, a neuronal specific nuclear protein in vertebrates. Development. 116:201-211.
25. Zausinger, S., Hungerhuber, E., Baethmann, A., Reulen, H., and Schmid-Elsaesser, R. 2000. Neurological impairment in rats after transient middle cerebral artery occlusion: a comparative study under various treatment paradigms. Brain Res. 863:94-105.
26. Frenkel, D., et al. 2003. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J. Immunol. 171:6549-6555.
27. Martinou, J.-C., and Green, D.R. 2001. Breaking the mitochondrial barrier. Nat. Rev. Mol. Cell Biol. 2:63-67.
28. Zamzami, N., and Kroemer, G. 2001. The mitochondrion in apoptosis: how Pandora's box opens. Nat. Rev. Mol. Cell Biol. 2:67-71.
29. Zou, H., Hanzel, W.J., Liu, X., Lutschg, A., and Wang, X. 1997. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 90:405-413.
30. Zou, H., Li, Y., Liu, X., and Wang, X. 1999. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274:11549-11556.
31. Srinivasula, S.M., Ahmad, M., Fernandes-Alnemri, T., and Alnemri, E.S. 1998. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell. 1:949-957.
32. Vieira, H.L.A., et al. 2000. Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator. Cell Death Differ. 7:1146-1154.
33. Jacotot, E., et al. 2001. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J. Exp. Med. 193:509-519.
34. Halestrap, A.P., and Brenner, C. 2003. The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. Curr. Med. Chem. 10:1507-1525.
35. Verrier, F., et al. 2004. Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis. Oncogene. 23:8049-8064.
36. Kanno, T., et al. 2004. Oxidative stress underlies the mechanisms for Ca2+-induced permeability transition of mitochondria. Free Radic. Res. 38:27-35.
37. Halestrap, A.P., Woodfield, K.Y., and Connern, C.P. 1997. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J. Biol. Chem. 272:3346-3354.
38. Nakagawa, Y. 2004. Initiation of apoptotic signal by the peroxidation of cardiolipin of mitochondria. Ann. N. Y. Acad. Sci. 1011:177-184.
39. Decaudin, D., et al. 2002. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res. 62:1388-1393.
40. Hirsch, T., et al. 1998. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. Exp. Cell Res. 241:426-434.
41. Haouzi, D., et al. 2002. Mitochondrial permeability transition as a novel principle of hepatorenal toxicity in vivo. Apoptosis. 7:395-405.
42. Duan, S., et al. 2003. Mitochondrial outer membrane permeability change and hypersensitivity to digitonin early in staurosporine-induced apoptosis. J. Biol. Chem. 278:1346-1353.
43. Cheng, E.H.-Y., Sheiko, T.V., Fisher, J.K., Craigen, W.J., and Korsmeyer, S.J. 2003. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science. 301:513-517.
44. Brenner, C., Marzo, I., de Araujo Vieira, H.L., and Kroemer, G. 2000. Purification and liposomal reconstitution of permeability transition pore complex. Methods Enzymol. 322:243-252.
45. Kokoszka, J.E., et al. 2004. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature. 427:461-465.
46. Halestrap, A.P. 2004. Mitochondrial permeability: dual role for the ADP/ATP translocator? Nature. 430:984.
47. Aarnoutse, R.E., et al. 2002. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob. Agents Chemother. 46:884-886.
48. Raines, C.P., et al. 2000. Safety, tolerability, and antiretroviral effects of ritonavir- nelfinavir combination therapy administered for 48 weeks. J. Acquir. Immune Defic. Syndr. 25:322-328.
49. MacManus, J.P., et al. 2003. Absence of the transcription factor E2F1 attenuates brain injury and improves behavior after focal ischemia in mice. J. Cereb. Blood Flow Metab. 23:1020-1028.
50. Preston, E., and Webster, J. 2000. Spectrophotometric measurement of experimental brain injury. J. Neurosci. Methods. 94:187-192.
51. Melanson-Drapeau, L., et al. 2003. Oligodendrocyte progenitor enrichment in the connexin32 null-mutant mouse. J. Neurosci. 23:1759-1768.
52. Sawada, M., et al. 2003. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat. Cell Biol. 5:320-329.
53. Forcet, C., et al. 2001. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc. Natl. Acad. Sci. U. S. A. 98:3416-3421.
54. Trushin, S.A., et al. 2003. Protein kinase Calpha (PKCalpha) acts upstream of PKCtheta to activate IkappaB kinase and NF-kappaB in T lymphocytes. Mol. Cell. Biol. 23:7068-7081.
55. Seglen, P.O. 1976. Preparation of isolated rat liver cells. Methods Cell Biol. 13:29-83.
56. Zamzami, N., et al. 1995. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 181:1661-1672.
57. Nie, Z., et al. 2002. HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ. 9:1172-1184.
58. Susin, S.A., Larochette, N., Geuskens, M., and Kroemer, G. 2000. Purification of mitochondria for apoptosis assays. Methods Enzymol. 322:205-208.
59. Blachly-Dyson, E., et al. 1993. Cloning and functional expression in yeast of two human isoforms of the outer mitochondrial membrane channel, the voltage-dependent anion channel. J. Biol. Chem. 268:1835-1841.
60. Blachly-Dyson, E., Song, J., Wolfgang, W.J., Colombini, M., and Forte, M. 1997. Multicopy suppressors of phenotypes resulting from the absence of yeast VDAC encode a VDAC-like protein. Mol. Cell. Biol. 17:5727-5738.
61. Drgon, T., Sabova, L., Nelson, N., and Kolarov, J. 1991. ADP/ATP translocator is essential only for anaerobic growth of yeast Saccharomyces cerevisiae. FEBS Lett. 289:159-162.
62. Macreadie, I.G., Arunagiri, C.K., Hewish, D.R., White, J.F., and Azad, A.A. 1996. Extracellular addition of a domain of HIV-1 Vpr containing the amino acid sequence motif H(S/F)RIG causes cell membrane permeabilization and death. Mol. Microbiol. 19:1185-1192.
63. Marzo, I., Brenner, C., and Kroemer, G. 1998. The central role of the mitochondrial megachannel in apoptosis: evidence obtained with intact cells, isolated mitochondria, and purified protein complexes. Biomed. Pharmacother. 52:248-251.
64. Belzacq, A.S., et al. 2003. Bcl-2 and Bax modulate adenine nucleotide translocase activity. Cancer Res. 63:541-546.
65. McMartin, C., and Bohacek, R.S. 1997. QXP: powerful, rapid computer algorithms for structure-based drug design. J. Comput. Aided Mol. Des. 11:333-344.
66. Pebay-Peyroula, E., et al. 2003. Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside. Nature. 426:39-44.